Biosimilars
Biosimilars
New Study: States Could Save Up to $1.8 Billion Annually by Prioritizing Lower-Cost Biosimilar Medicines
At a time when states across the country are grappling with significant budget challenges, a new study from the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – finds that state employee health plans could save up to $1.8 ...
Biosimilars
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Biosimilars
Fixing The Regulatory Flaws Biosimilars Face Will Help Patients
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process. These negotiations are essentially a means to impose price controls on selected medicines. If the Trump Administration truly wants to help patients, ...
Biosimilars
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Biosimilars
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Biosimilars
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could have ...
Biosimilars
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Biosimilars
NEW ISSUE BRIEF: Biosimilar Competition Lowers Patient Drug Costs, New Competition Will Bring Even More Savings
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute provides the latest evidence that biosimilar competition is saving patients billions – and additional competition would increase savings even more. Click to download the brief From 2019-2023, patients saved $15 billion ...
New Study: States Could Save Up to $1.8 Billion Annually by Prioritizing Lower-Cost Biosimilar Medicines
At a time when states across the country are grappling with significant budget challenges, a new study from the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – finds that state employee health plans could save up to $1.8 ...
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Fixing The Regulatory Flaws Biosimilars Face Will Help Patients
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process. These negotiations are essentially a means to impose price controls on selected medicines. If the Trump Administration truly wants to help patients, ...
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could have ...
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
NEW ISSUE BRIEF: Biosimilar Competition Lowers Patient Drug Costs, New Competition Will Bring Even More Savings
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute provides the latest evidence that biosimilar competition is saving patients billions – and additional competition would increase savings even more. Click to download the brief From 2019-2023, patients saved $15 billion ...